Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape
Cabaletta Bio shares rose about 11% premarket Thursday after insider-buying reports, trading at $2.60 versus Wednesday’s $2.34 close. CEO Steven Nichtberger bought 45,000 shares Jan. 21, with other executives and directors also purchasing stock, SEC filings show. Trading volume Wednesday hit 2.09 million shares. The company is developing an experimental CD19 CAR-T therapy for autoimmune diseases.